MedStartrLet’s Transform Healthcare Faster Together.
MedStartr Capital is investing in over 100 of the most crowd-validated new ideas transforming care from a new family of funds designed to enable aligned, impact-driven healthcare investors and stakeholders to become stockholders in the future of care.
An AI-empowered, diversified healthcare portfolio
We invest in impactful innovations — those that lower the cost of care while improving quality and access — crowd-validated by MedStartr's algorithms, credentialed crowds, AI agents, and proprietary data. 85% of investments are expected to be AI-empowered.
Rare innovation, scarce capital
Many healthcare unicorns will emerge over the next five years, yet innovation capital is constrained after 2023–25 underperformance. Less competition for the best deals while capital is scarce.
126 metrics no spreadsheet can replicate
Since 2012, engagement across MedStartr.com and 1,283 live events in 44 cities feeds predictive algorithms — including founder grit, ethics, and pilot-interest signals available nowhere else.
22× more likely to succeed
Ideation, validation, acceleration, coordination, and integration — a five-stage system that de-risks every step. MedStartr's record runs roughly 7× the category average over seven years.
Agents that show their work
Syggy matches users to innovations and gathers signal; Fyggy predicts success with fully auditable math. MedStartr.ai launches Q3 2026, multiplying the data engine 20×.
Diversified across healthcare and medicine
We plan to invest in over 100 of the best new companies in healthcare in the next four years, 85% of which we expect to be AI-empowered.
Target allocation by sub-sector (sums to 100%); illustrative and subject to change. CAGR figures are third-party sub-sector estimates, not fund projections.
From our crowd, to predictions, to three levels of acceleration
The MedStartr System is one connected engine: a credentialed crowd generates proprietary data, that data trains our predictions, our predictions and mentor network select and de-risk the best teams, and our three-stage accelerator grows them to exit. Companies validated by the System are 22× more likely to succeed.
Four stakeholders, one safe space for innovation
The four figures in the MedStartr logo are the four stakeholders of healthcare, holding hands around the cross of care. Across our events, platforms, and contests, we ask each whether an innovation is worth backing:
When all four are ready to try, buy, pilot, partner, and mentor an innovation, they create a safe space — for founders to build, and for investors to commit time and capital with conviction.
We’ve built that crowd since 2008 — running 120+ contests and grand challenges and developing crowd-data methods and algorithms for HHS, the AMA, AHA, AMIA, Aetna, Takeda, GE, BCBS, Ochsner, and 100+ other leading organizations. Winners like Medable and Unite Us grew into billion-dollar companies. In 2017 we began investing in the winners — and our proprietary “crowd-validation” methodology, algorithms, and AI remain our edge.
The world's largest healthcare innovation dataset
Tens of millions of interactions on our platforms and at 1,200+ live events across 44 cities feed our predictive algorithms — 126 metrics per company, including proprietary signals like founder grit, ethics, and pilot interest that exist nowhere else. MedStartr.ai, launching in Q3 2026, will add historical data and an order-of-magnitude more depth across 16,000+ innovations with more arriving daily.
Two AI agents that show their work
Data becomes decisions through two agents. Syggy matches millions of credentialed users to innovations and gathers signal at scale. Fyggy predicts which companies will succeed in the next 18–24 months — and shows all of its math, with no hallucinations. Coupled with intense due diligence and founder psychometrics, the System sees exponential growth before it happens.
1,400+ mentors who advise, partner, and invest
Our 1,400+ MedStartr Mentors, a world-class Advisory Board, and 20+ Venture Partners across 20 cities advise, partner, pilot, and invest in our portfolio companies. When a company stalls, we activate a Phoenix turnaround team — one such team fixed a company's strategy and earned 15× with new investors the next month.
Three stages of acceleration to exit
Teams that pass due diligence are invited into a three-stage program that grows them from launch to integration and exit.
3-year program: 40 hours of training, $350K in in-kind services, monthly calls, and demo days at three stages of growth.
Revenue-growth accelerator with partners, monitored by our Mission Control AI early-warning system — better deals, fewer pitfalls, faster exits.
Partners, payers, pharma, and health systems adopt our companies at scale, driving rapid adoption and exits.
The result: Fund II produced 4.0× gains (MOIC) to date
The System's logical outcome. All investments and unrealized gains from inception (2/19/2019) through 3/31/2026; years 2–5 were significantly affected by the COVID-19 pandemic. Past performance is not a predictor of future results.
12 companies, 19 deals, repeatable winners
Multiples reflect valuation growth since investment as of 3/31/2026, per most recent funding rounds. Conservative estimates for SAFEs, debt, and equity. Past performance is not a predictor of future results.
150+ years of combined healthcare and venture expertise
Backed by 1,400+ MedStartr Mentors and 20+ Venture Partners across 20 cities.
Apply to Join Us
MedStartr invites vetted healthcare leaders to advise, partner, pilot, and invest alongside Fund III across 20 cities.
1,400+ Mentors and a world-class Advisory Board
Every MedStartr user is credentialed; the best are vetted and invited to mentor, advise, partner, pilot, and invest in our portfolio companies. A few of them:
MedStartr Venture Partners and staff average 7.4 years with MedStartr, engaging locally to scale globally.
Apply to Join Us
MedStartr invites vetted healthcare leaders to advise, partner, pilot, and invest alongside Fund III across 20 cities.
Two paths into MVF III. Both open now.
Accredited investors join the 506(c) direct round. All other U.S. investors can participate through our Republic Reg CF campaign (up to $5M). Answer one question to find your path.
Frequently asked questions
What is MedStartr Venture Fund III?
MedStartr Venture Fund III (MVF III) is a $40M early-stage healthcare venture fund investing in AI-empowered companies from seed to Series A. Investments are crowd-validated on the MedStartr platform, AI-predicted by proprietary models, and accelerated through a proven three-stage program.
What is the fund's track record?
Fund II has produced a 4.0× MOIC in gains to date, with a 33% gross IRR and 27% net IRR since inception (TVPI 2.91, DPI 24.5%, as of 3/31/2026). MOIC reflects total value including unrealized gains, not realized cash. Companies validated by the MedStartr System have been 22× more likely to succeed. Past performance is not a predictor of future results.
Who can invest, and what is the minimum?
Accredited investors can invest in the 506(c) direct round with a $250,000 minimum. All U.S. investors can participate through our Regulation CF campaign on Republic (up to $5M).
How is MVF III different from other healthcare funds?
MedStartr has run a healthcare innovation platform since 2012, generating proprietary data across 1,200+ live events in 44 cities and 126 metrics per company. Two AI agents — Syggy and Fyggy — turn that data into predictions, and a 1,400+ mentor network de-risks and accelerates portfolio companies.
How can I join as a mentor or venture partner?
MedStartr invites vetted healthcare leaders to join as mentors or venture partners across 20 cities. Apply through the Join Us options on this site to advise, partner, pilot, and invest alongside the fund.